Day: September 20, 2021

Patent estate also expanded by the issuance of 23 additional patents in international markets Humacyte now owns or licenses 119 patents covering its proprietary platformDURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the issuance of three additional U.S. patents covering its proprietary technology platform. Included in the new patents are additional claims related to the Human Acellular Vessels (HAVs), engineered, off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. New U.S. Patents 10,934,532 and 10,947,498, both titled “Tissue-engineered constructs,” expand upon existing patents encompassing...

  Paris, September 20, 2021,   Disclosure of Transactions in Own Shares   In accordance with the authorization given by the shareholders’ annual meeting on July 6, 2021 to trade on its own shares and pursuant to applicable law on share repurchase, Kering (LEI: 549300VGEJKB7SVUZR78) declares the following purchases of its own shares (FR0000121485) from September 13 to 17, 2021:Issuer’s name Issuer’s identifying code Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares Market (MIC code)KERING 549300VGEJKB7SVUZR78 13/09/2021 FR0000121485 13,181 684.7668 XPARKERING 549300VGEJKB7SVUZR78 13/09/2021 FR0000121485 675 682.6511 CEUXKERING 549300VGEJKB7SVUZR78 13/09/2021 FR0000121485...

Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA–CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETESAT278 delivers significantly accelerated PK/PD profile compared to NovoRapid® Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices Potential to enable more effective disease management for insulin resistant patients requiring >200 units of insulin per dayCambridge, UK, 20 September 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its ultra-concentrated ultra-rapid acting insulin, AT278 met all of its primary and secondary...

Sify’s facility at Vashi was the first of the 10 Company-owned Data CentersChennai, Tamil Nadu, Sept. 20, 2021 (GLOBE NEWSWIRE) — Sify Technologies Limited (NASDAQ: SIFY), India’s most comprehensive ICT solutions provider today announced that its Data Center at Vashi, the first commercial Data Center in India, completed 21 years of uninterrupted operations. Sify Technologies expanded into the Data Center business in the year 2000. Sify has built and today operates 10 carrier-neutral Data Centers, currently offering more than 70 MW IT Power. Following the facility at Vashi, Sify followed up with larger capacities in Bangalore, Chennai, Airoli, Noida, Rabale, Hyderabad and Kolkata and aims to add 200 MW in the next 4 years. Through CloudCover, Sify also services a network of 49 Data Centers across India. Delighted...

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Jae Park, M.D., acting Chief of Cellular Therapeutics at Memorial Sloan Kettering Cancer Center in New York, to its Scientific Advisory Board (SAB). Dr. Park, widely recognized as one of the world experts in cell therapies, is the leading principal investigator of several clinical trials in patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia. “We are honored to welcome Dr. Park to our Scientific Advisory Board,” said Rafael Amado, M.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene....

SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) — Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that according to a preliminary list of initial public offering (IPO) additions to the Russell indexes, the company will be added to the Russell 2000 Index effective Sept. 20, 2021. “We are pleased to be included in the Russell 2000 Index following our transition to a public company in July,” said Gregory C. Critchfield, M.D., M.S., Chairman and CEO of Sera Prognostics. “This is the latest milestone for our company that will expand awareness of Sera within the investment community as we scale our PreTRM® test and expand revenue to build shareholder value.” About Sera Prognostics,...

Grand Prize Winner to Receive Ultimate Prize Pack MINNEAPOLIS, Sept. 20, 2021 (GLOBE NEWSWIRE) — SharpLink Gaming Ltd. (Nasdaq: SBET) (“SharpLink” or the “Company”), a pioneer of game-changing technological solutions and experience-based services for the U.S. online sports betting industry, today announced that the Company is teaming with NBC Sports to launch a new, interactive, free-to-play online game for the 43rd Ryder Cup to be held at Whistling Straits in Kohler, Wisconsin from September 24-26, 2021. Established in 1927, the Ryder Cup is a major golf competition that occurs every two years and pits 24 of the world’s best golfers comprising Team USA and Team Europe in a head-to-head match play competition. The Ryder Cup Fantasy online game will be available on www.RyderCup.com and the official Ryder Cup mobile apps for iOS...